**Prophylactic inhibition of colonization by *Streptococcus pneumoniae* with
the secondary bile acid metabolite deoxycholic acid**

Jorge E. Vidal^{1,#}, Meagan N. Wier¹, Uriel Angulo-Zamudio², Erin McDevitt¹, Ana G. Jop Vidal¹, Babek
Alibayov¹, Anna Scasny¹, Sandy M. Wong¹, Brian J. Akerley¹, and Larry S. McDaniel¹

¹Department of Microbiology and Immunology, University of Mississippi Medical Center, Jackson,
MS, USA. ²University of Sinaloa School of Medicine, Culiacan Sinaloa, Mexico

Running title: Eradication of Spn from the nasopharynx with DoC

Address correspondence to:

Jorge E. Vidal, PhD. Department of Microbiology and Immunology, University of Mississippi Medical
Center. 2500 North State St, Jackson MS 39216

Abstract

Streptococcus pneumoniae (Spn) colonizes the nasopharynx of children and the elderly but also kills millions worldwide yearly. The secondary bile acid metabolite, deoxycholic acid (DoC), affects the viability of human pathogens but also plays multiple roles in host physiology. We assessed *in vitro* the antimicrobial activity of DoC and investigated its potential to eradicate Spn colonization using an *ex vivo* model of human nasopharyngeal colonization and an *in vivo* mouse model of colonization. At a physiological concentration DoC (0.5 mg/ml; 1.27 mM) killed all tested Spn strains (N=48) two h post-inoculation. The *ex-vivo* model of nasopharyngeal colonization showed that DoC eradicated colonization by Spn strains as soon as 10 min post-exposure. The mechanism of action did not involve activation of autolysis since the autolysis-defective double mutants $\Delta lytA\Delta lytC$ and $\Delta spxB\Delta lctO$ were as susceptible to DoC as was the wild-type (WT). Oral streptococcal species (N=20), however, were not susceptible to DoC (0.5 mg/ml). Unlike trimethoprim, whose spontaneous resistance frequency (srF) for TIGR4 or EF3030 was $\geq 1 \times 10^{-9}$, no spontaneous resistance was observed with DoC (srF $\geq 1 \times 10^{-12}$). Finally, the efficacy of DoC to eradicate Spn colonization was assessed *in vivo* using a topical route via intranasal (i.n.) administration and as a prophylactic treatment. Mice challenged with Spn EF3030 carried a median of 4.05×10^5 cfu/ml four days post-inoculation compared to 6.67×10^4 cfu/ml for mice treated with DoC. Mice in the prophylactic group had a ~99% reduction of the pneumococcal density (median, 2.61×10^3 cfu/ml). Thus, DoC, an endogenous human bile salt, has therapeutic potential against Spn.

40 Introduction

41 *Streptococcus pneumoniae* (Spn) colonizes millions worldwide yearly, with a colonization
 42 prevalence particularly high in children and the elderly (1-3). In children, the prevalence of
 43 pneumococcal carriage can be as high as 90% in those from developing countries, or between 25-
 44 40% in children from industrialized nations (1, 4-7). There are also certain populations within
 45 developed countries with increased carriage rates. For example, in a study by Sutcliffe et al (2019)
 46 73.5% of children less than five, living in the US but of the Navajo nation, carried the pneumococcus
 47 in the upper airways (8). Along the same lines, carriage of Spn in adults 18-49.9 years of age can be
 48 as high as 50% (8, 9) while pneumococcal carriage in a more vulnerable population, those older than
 49 60, is similar (10) but increases in individuals colonized by the influenza virus (5). Although it is early
 50 to draw conclusions, pneumococcal carriage is expected to increase in individuals colonized with
 51 SARS-CoV-2 whereby we may experience a surge of pneumococcal disease (PD) cases in the next
 52 few years (11).

53 Pneumococcal carriage is a risk for developing PD and therefore it is considered an
 54 immediate and necessary precursor of PD (1, 2, 12, 13). An important intervention with a
 55 demonstrated positive impact on Spn carriage has been vaccination (14). Pneumococcal conjugated
 56 vaccines (PCV) were introduced in many parts of the world since 2001 when PCV7 was licensed in
 57 the US (15, 16). The introduction of these vaccines reduced the burden of PD caused by vaccine
 58 serotypes on a global scale and has also decreased nasopharyngeal carriage of pneumococcal
 59 vaccine types in vaccinated populations (14, 17). However, the overall carriage prevalence has not
 60 changed because of a phenomenon called “serotype replacement”, i.e., vaccine-escape strains have
 61 replaced vaccine type (VT) strains in the nasopharynx, resulting in pneumococcal carriage rates

similar to those observed prior to the introduction of vaccines (18-20). Therefore, additional interventions, or prophylactic strategies, are needed to aid reduce the burden of colonization.

Pathogenic and normal flora bacteria are susceptible to bile from different mammals (21-23). Recent studies have demonstrated that the lack of primary and secondary bile acid metabolites is implicated in the development of intestinal infectious disease (21-23). Bile consists of ~95% water in which are dissolved a number of endogenous solid constituents including bile salts, bilirubin phospholipid, cholesterol, amino acids, steroids, enzymes, porphyrins, vitamins, and heavy metals (24). Bile salts are the major organic solutes in bile and normally function to emulsify dietary fats and facilitate their intestinal absorption. The two main primary bile salts that are synthesized in the mammalian liver are cholic acid, and chenodeoxycholic acid (24, 25). Intestinal bacteria then produce “secondary bile acids” through enzymatic reactions, with the addition of two hydroxyl groups to cholic acid producing one of the most abundant secondary metabolites, deoxycholic acid (DoC) (24, 26). Endogenously-produced, secondary bile acids, have widespread effects on the host and resident microbiota and have therefore been used to treat different diseases (26). Cholic acid is used to treat patients with genetic deficiencies in the synthesis of bile acids due to single enzyme deficiencies; the typical dose is 10 to 15 mg/kg once daily (27). DoC has been utilized in humans at a concentration of 15 mg/kg/day to decrease plasma high-density lipoprotein (HDL)-cholesterol and low-density lipoprotein (LDL)-cholesterol (27) and it is also FDA-approved to reduce fat deposits (28, 29).

In addition to their physiological role in digesting lipids, bile acids are important regulators of intestinal homeostasis by activating receptors on intestinal cells and stimulating the immune response (25). In germ-free mice or mice treated with antibiotics to deplete the intestinal bacterial flora, the lack of secondary bile acids caused a deficient TLR7-MyD88 signaling in plasmacytoid

dendritic cells that resulted in an increased susceptibility to systemic chikungunya infection (21). Another secondary bile acid, ursodeoxycholic acid, inhibited *in vitro* toxin production, growth and spore germination of *Clostridiodes difficile* strains and contributed to colonization resistance in an *in vivo* mouse model of *C. difficile* disease (CDI) (30). Administration of clindamycin reduced intestinal levels of valerate and DoC, increasing viable counts of *C. difficile* in a CDI chemostat infection model (31). A similar treatment of mice with clindamycin caused decreased intestinal DoC leading to increased *Campylobacter jejuni*-induced colitis (22). The growth of another intestinal pathogen, *Clostridium perfringens*, was inhibited *in vitro* with as low as 50 μ M of DoC. Using an animal model of necrotic enteritis (NE), and supplementation of DoC in the diet (e.g., 1.5 g/kg) decreased intestinal inflammation and NE-associated intestinal cell death and apoptosis (23).

In vitro studies demonstrated synergistic antibiotic activity when Doc (2.5 mg/ml) was combined with vancomycin, or with vancomycin and furazolidone, to treat clinically-important antibiotic resistant pathogens (32). Synergism between DoC, or lithocholic acid, and tryptophan-derived antibiotics secreted by intestinal bacteria inhibited bacterial division of *C. difficile* strains (33). In this study we assessed the antimicrobial activity of DoC against a collection of Spn strains, including reference strains, Spn isolated from cases of pneumococcal disease, and strains resistant to multiple antibiotics. The mechanistic basis for the observed sensitivity to DoC was investigated using knockout mutants in different autolytic mechanisms. We also adapted an *ex vivo* model of nasopharyngeal colonization to investigate the efficacy of DoC to eradicate Spn colonization and finally developed an *in vivo* prophylactic mouse model to demonstrate that administration of DoC prevented Spn colonization.

Results

Deoxycholic acid (DoC) eradicates cultures of drug-resistant *S. pneumoniae*. We challenged reference strains D39 and TIGR4 and drug-resistant Spn 19A and 19F vaccine-serotypes strains with increasing dosages of DoC and incubated for 2 h. Whereas untreated bacteria grew at $>10^8$ cfu/ml, all five pneumococcal strains treated with DoC were killed within 2 h with 0.5 mg/ml (1.27 mM). Except for strain D39, all other vaccine serotype Spn strains were also killed with 250 μ g/ml of DoC (Fig. 1).

We then assess the antimicrobial efficacy of DoC (0.5 mg/ml) against 39 pneumococcal strains isolated from cases of pneumococcal disease. Strains represented all PCV13 vaccine serotypes, and at least two strains of each vaccine serotype were challenged. Supplemental Table 1 confirmed that 0.5 mg/ml (1.27 mM) of DoC incubated for 2 h killed all assessed Spn strains. A MIC₉₀ of 0.5 mg/ml DoC was established.

A similar MIC [0.5 mg/ml (1.27 mM)] was obtained with reference strain TIGR4, or EF3030, assessed in cation-activated Mueller-Hinton broth (CAMHB) with 3% of lysed horse blood (LHB) and according to CLSI guidelines to assess resistance (34), or non-susceptibility, of Spn strains (Supplemental Fig. 1 and not shown). Whereas the density of TIGR4 inoculated in CAMHB and incubated overnight reached a density of 6.7×10^{10} cfu/ml, those cultures treated with DoC (1.27 mM) had a median density of 1.2×10^4 cfu/ml, a ~99.99% reduction in density after overnight incubation (Supplemental Fig. 1).

DoC eradicates MDR *S. pneumoniae* colonization in an *ex-vivo* model with human pharyngeal cells. To assess the potential of DoC to eradicate pneumococcal colonization, we performed experiments using an *ex-vivo* model of colonization. To create an abiotic substrate for pneumococci to colonize we used polarized human pharyngeal cells that had been fixed with paraformaldehyde.

131 These cell monolayers were infected with a MDR Spn strain GA47281, a vaccine strain serotype 19F
 132 bearing resistance to several antibiotics including erythromycin, meropenem, and cefuroxime.
 133 Infected human cells were incubated for 4 h to allow attachment of Spn and then planktonic
 134 bacteria were removed. Spn-colonized human cells were left untreated or challenged with different
 135 dosages of DoC and incubated for 2 h. All doses of DoC reduced the density of MDR pneumococci
 136 >90% after the 2 h incubation compared to untreated human pharyngeal cells which had a density
 137 of $\sim 1 \times 10^7$ cfu/ml of pneumococci (Fig. 2A). GA47281 bacteria were not recovered when
 138 pneumococci were treated with 0.5 mg/ml (1.27 mM). Confocal scanning laser microscopy, XY
 139 optical sections and 3D reconstructions, of cells infected with Spn confirmed that DoC had
 140 eradicated colonization by strain GA47281 (Fig. 2C) or colonization by strain TIGR4 (Fig. 2D) from
 141 human pharyngeal cells.

142 To determine the exposure time required to kill pneumococci, we performed a time course
 143 study treating MDR pneumococci colonizing human pharyngeal cells for up to one h with 0.5 mg/ml
 144 (1.27 mM). Interestingly, a ten-minute exposure time was enough to kill most attached MDR
 145 pneumococci (Fig. 2B). The antimicrobial effect did not change with a longer exposure time of 60
 146 min. These data indicate that 0.5 mg/ml (1.27 mM) of DoC rapidly eradicates MDR pneumococci
 147 that otherwise would have colonized human nasopharyngeal cells at a density $\sim 10^7$ cfu/ml (Fig. 2B).

148

149 **Spontaneous resistance to DoC (500 μ g/ml) was not developed by *S. pneumoniae* strains.** Spn
 150 strains develop spontaneous resistance to some antibiotics at a spontaneous mutation frequency
 151 $> 1 \times 10^{-8}$ (35). We assessed spontaneous resistance to DoC using antibiotic sensitive strains TIGR4 and
 152 EF3030. As expected, spontaneous resistance against trimethoprim developed at a frequency of
 153 $\geq 1.39 \times 10^{-9}$ when either pneumococcal strain was assessed (Fig. 3). Spontaneous resistance to DoC,

however, was not observed in any of the two strains tested even at a population density $>10^{12}$ cfu/ml (Fig. 3).

The mechanism of DoC-killing does not appear to trigger autolysis. Since the above experiments revealed that a short exposure time was sufficient to kill pneumococci, we hypothesized that an irreversible autolytic mechanism may have been triggered by DoC. Autolysis is mainly driven by autolysins LytA and LytC (36, 37) but hydrogen peroxide produced by the pneumococcus, through enzymes SpxB and LctO, also contributes to lysis of pneumococci (38-40). To assess this hypothesis, we utilized strain R6 wt, its isogenic $R6\Delta lytA\Delta lytC$ mutant and a double $R6\Delta spxB\Delta lctO$ mutant to assess the role of autolysis in the observed DoC-mediated bactericidal activity. Since autolysis can be measured by quantifying the release of extracellular (e)DNA, we first confirmed that the absence of the LytA and LytC autolysins, or SpxB and LctO, causes a decreased release of eDNA into the supernatant. After four hours of incubation, the eDNA released by R6 wt strain reached a median of 2.24×10^6 pg/ml, whereas $R6\Delta spxB\Delta lctO$ released a statistically different two-fold decreased amount of eDNA (median, 1.09×10^6 pg/ml) in the supernatant (Fig. 4A). As expected, the autolysin double mutant $R6\Delta lytA\Delta lytC$ yielded a ~14-fold reduced amount of eDNA (median, 1.55×10^5 pg/ml) (Fig. 4A) compared to R6 wt.

These two mutant strains with an impaired autolysis phenotype were then challenged with DoC [0.5 mg/ml (1.27 mM)] and treated and untreated bacteria were incubated for 1 h. Results in Fig. 4B showed a >90% significant reduction (i.e., killing) of the population of R6 pneumococci after 1 h of incubation. The density of the $R6\Delta spxB\Delta lctO$ isogenic mutant (not shown) or the $R6\Delta lytA\Delta lytC$ mutant (Fig. 4B) was similarly reduced after 1 h incubation period with DoC, indicating that the mechanism by which DoC kill pneumococci is not by triggering autolysis.

177

178 **DoC does not affect viability of normal flora streptococci.** We next investigated whether the MIC₉₀
 179 of DoC that eradicates Spn strains [0.5 mg/ml (1.27 mM)] within 2 h of incubation would have the
 180 same bactericidal effect against other streptococci that reside in the oral cavity. As a positive control
 181 we utilized Spn reference strain EF3030 (41, 42). The median density of EF3030 untreated cultures
 182 was 3.37×10^7 cfu/ml whereas those treated with 0.5 mg/ml DoC for 2 h had a median density of
 183 3.1×10^2 cfu/ml, and therefore DoC killed 99.99% of the bacterial population (Fig. 5A). However, the
 184 same dose of DoC incubated for 2 h did not significantly affect the viability of *S. oralis* (Fig. 5B), *S.*
 185 *mutans*, (Fig. 5C) *S. gordonii*, (Fig. 5D) and induced a two-log reduction of the density of *S.*
 186 *anginosus*. (Fig. 5E). An additional 16 different streptococcal species were treated with DoC [0.5
 187 mg/ml (1.27 mM)] for two hours and, except for *S. pseudopneumoniae* and *S. salivarius* that were
 188 susceptible, cultures of all other species were not affected (Table 1).

189

190 **Standardizing the mouse model of pneumococcal carriage to assess the efficacy of DoC to**
 191 **eradicate nasopharyngeal colonization.** The bacterial inoculum utilized in a mouse model of
 192 pneumococcal colonization is usually $\sim 1 \times 10^7$ cfu and nasal washes through the trachea are
 193 performed to assess colonization (43, 44). We first standardized the removal of a defined section of
 194 nasopharyngeal tissue consisting of the intact nasal septum (Fig. 6A) from colonized mice and
 195 confirmed by histological analysis the presence of typical nasopharyngeal tissue including microvilli,
 196 and pseudostratified, squamous epithelium overlaying by loose connective tissue including blood
 197 vessels with erythrocytes (Fig. 6B). Since our goal was to assess the efficacy of DoC to reduce, and/or
 198 inhibits, nasopharyngeal colonization we investigated a low inoculum density of Spn EF3030 that
 199 would sustain colonization of mice, but avoided using a non-natural (i.e., heavy) inoculum. Our

experiments demonstrated that inoculating $\sim 1 \times 10^5$ cfu in the nostrils of mice allowed nasopharyngeal colonization for up to four days at a median density of 2.49×10^5 cfu/organ (Fig. 6D). We additionally removed the trachea and lungs and demonstrated consistent Spn colonization of the trachea, at a low density of 9.0×10^2 cfu/organ, but colonization of the lungs was not observed (Fig. 6D). Encapsulated Spn were detected using an anti-S19-Alexa-555 antibody and were identified both in nasopharyngeal homogenates (Fig. 6C) and colonizing the nasopharyngeal tissue (Fig. 6E). Microinvasion into the nasopharyngeal epithelium was also observed (Fig. 6E).

Deoxycholic acid (DoC) decreased *in vivo* colonization by *S. pneumoniae* strain EF3030 in a mouse model of nasopharyngeal carriage. We then assessed the efficacy of DoC to eradicate colonization using three groups of mice (N=8). Groups 1 and 2 drank regular water while the drinking water of group 3 was supplemented with DoC at a concentration of 0.2 $\mu\text{g/ml}$ (i.e., 0.02%) six days prior to infection and remained in their drinking water throughout the experiment (Fig. 7A). All three groups were then challenged i.n. with Spn EF3030 ($\sim 1 \times 10^5$ cfu) and 24 h post-infection, mice in groups 1 and 2 were treated twice a day i.n. with 10 μl of a PBS solution or DoC (2 mg/ml), respectively. Mice were euthanized 10 days after initiating the prophylactic regimen (i.e., oral administration) in drinking water, or four days after placebo or DoC topical nasopharyngeal treatment began (Fig. 7A).

Because of the oral and topical administration of DoC, we monitored the weight of mice daily and no statistically significant difference in weight was observed between day one and the end of the experiment in groups 1, 2, and 3 (Fig. 7B). The colonization density of Spn was determined by dilution and plating of nasopharyngeal homogenates (Fig. 7C). The median density of Spn in the control group was 4.05×10^5 cfu/ml (25th percentile, 2.50×10^4 ; 75th percentile, 5.60×10^5) whereas mice in the topical DoC-nostril group had a median density of 6.67×10^4 cfu/ml (25th percentile, 1.15

$\times 10^5$; 75th percentile, 5.94×10^5). Although slightly reduced compared with the control group, this colonization density was not statistically different. However, mice in the prophylactic DoC administration group had a median Spn density of 2.61×10^3 cfu/ml (25th percentile, 1.5×10^3 ; 75th percentile, 2.03×10^4) and therefore, a significant reduction of nasopharyngeal colonization density (e.g., 99.36% reduction) was achieved compared to the control group. We further extracted DNA from those nasopharyngeal homogenates and the purified DNA was utilized as template in Spn-specific quantitative (q)PCR reactions. qPCR reactions confirmed a statistically significant decreased density in the oral administration DoC-water group (median, 1.77×10^4 genome equivalents/ml) compared with the control group (media, 6.70×10^5 genome equivalents/ml) or with the topical DoC-nostril group (media, 1.15×10^5 genome equivalents/ml) (Fig. 7D).

Discussion

We demonstrated that the prophylactic treatment through the oral route with DoC protected mice from nasopharyngeal colonization with Spn strain EF3030. We also described in the current study a rapid antimicrobial effect of DoC against Spn strains, including reference strains, recent invasive isolates and multidrug resistant strains. DoC-susceptible strains included all PCV13 serotypes, strains bearing resistance to first-line antibiotics utilized to treat pneumococcal disease such as beta-lactams and macrolides (45, 46), and last-resort antibiotics such as meropenem and linezolid. Killing of Spn occurred with 1.27 mM, which is below the upper physiological limit (i.e., 2 mM) of free, unconjugated, bile acids in the intestine although the post-prandial concentration of conjugated bile acids can be as high as 10 mM (47, 48). Remarkably, oral administration of DoC during 10 days by supplementing the drinking water of mice with 0.2 μ g/ml (0.5 μ M), inhibited nasopharyngeal colonization reducing the pneumococcal density by ~99%. Since adult mice (20-25

g) drink a minimum of 3 ml of water per day (49), this oral administration via drinking water reached a dosage of ~0.6 mg/day (~24 mg/kg/day).

DoC is a secondary bile acid synthesized by the intestinal microbiota from cholic acid and then rapidly absorbed in the intestine (24, 26), thereby it is likely that the concentration of DoC in blood rapidly increased and stayed at similar levels throughout the prophylactic treatment. Whether the level of DoC in circulation directly caused the reduction of the colonization density by means of the DoC-antimicrobial activity, or by means of its immunomodulatory activities, is currently under investigation in our laboratories. Bile produced by mammals has bacteriostatic activity keeping the sterility of the biliary tree, thereby an imbalance in the synthesis of bile acids, among other negative effects, is associated with the overgrowth of bacteria in the small intestine and with inflammation (50). For example, when the intestinal DoC increases the synthesis and secretion of mucus increases and induces the synthesis of immunoregulatory cytokines including the release of human β -defensins (50-52).

DoC is the most abundant secondary bile acid in serum of both mice and humans, with concentrations in healthy subjects ranging from 100 nM to 1 μ M (53, 54). Individuals with deficiencies in bile salts have problems to emulsify fat leading to intestinal disorders that have been treated by manipulating intestinal levels of bile acids (51). Cholic acid is used to treat patients with genetic deficiencies in the synthesis of bile acids due to single enzyme deficiencies; the typical dose is 10 to 15 mg/kg once daily (27). Specifically, DoC has been utilized in humans at a concentration of 15 mg/kg/day to decrease plasma high-density lipoprotein (HDL)-cholesterol and low-density lipoprotein (LDL)-cholesterol (27). Thus, the prophylactic dosage of oral DoC that inhibited *Spn* colonization in mice (24 mg/kg/day) was similar to that utilized to treat metabolic diseases in humans. More recent studies demonstrated that DoC (50-150 μ M) and ursodeoxycholic acid (UDA)

regulates colonic wound healing using a mouse model of colonic epithelial restitution *in vivo* by administering bile acids at a concentration of 30 mg/kg/day via rectal gavage (55). When administered to mice at a similar concentration, DoC and UDA prevented *C. jejuni*-induced colitis and CDI, respectively. Whereas DoC did not affect viability of *C. jejuni* strains but enhanced an immune response against the pathogen, UDA (3.8 mM) directly decreased the viability of *C. difficile* and directly inhibited sporulation.

Spn strains are “dissolved” in rabbit bile (56), and this is the basis of a phenotypic assay (i.e., bile solubility test) utilized to differentiate Spn strains from other α -hemolytic streptococci (57, 58). At a more physiological concentration, such as that utilized in the current study (1.27 mM), DoC specifically killed Spn strains but had little to no activity against other streptococci. Although the bile solubility test measures turbidity by a subjective visual method rather than viability, bile solubility of streptococci using a semi-quantitative assay correlated with our studies of bacterial viability after a challenge with DoC (59). Similar to our MIC studies, the semi-quantitative assay identified Spn strains having the highest solubility in bile followed by strains with intermediate solubility such as *S. pseudopneumoniae* but all other streptococci were not soluble in bile (59).

Reports describing Spn strains that were not soluble in DoC using the subjective visual readout are available; however, neither the semiquantitative assay nor our viability screening identified strains reduced in or lacking susceptibility to DoC (60). The possibility remains that some pneumococcal strains isolated from pneumococcal disease cases, or those colonizing healthy individuals, are naturally resistant to DoC. Spontaneous resistance to DoC when assessed using strains TIGR4 and EF3030 was not achieved even at bacterial populations $>10^{12}$ cfu/ml. The same strains, when challenged with trimethoprim, generated spontaneous resistant bacteria at a frequency of $\geq 1.39 \times 10^{-9}$. A similar spontaneous resistance frequency to trimethoprim (35), to that

found in the current study, or spontaneous mutation to optochin (61) have been reported for other Spn strains.

Given the very short treatment with DoC (~10 min) to reach a MIC *in vitro*, the current study assessed whether topical administration of DoC in the upper airways will result in eradication of colonization. However, mice infected with strain EF3030 and treated with DoC in the nares showed only a slight, but non-significant, reduction of the pneumococcal density. There are a number of reasons to explain the failure to eradicate colonization via the topical route. For example, the small nasal vestibule of mice may have resulted in failure of the DoC to reach all of the nasopharyngeal tissue and/or DoC may have been absorbed before reaching pneumococcal cells. Perhaps a lower pneumococcal carriage density, longer exposure to DoC in the upper airways, or a higher volume of DoC administered into the nostrils would have resulted in a further decrease in bacterial density. Microinvasion of pneumococcus into the nasopharyngeal epithelium observed in this study, and elsewhere (62), could have been also factor for the failure of the topical route.

Earlier biochemical studies suggested that an autolysin(s) was responsible for the lysis of pneumococci in DoC (63). If this is true, such an autolysin should be other than the major LytA or LytC autolysins since our experiments using two different autolysis defective mutants demonstrated similar DoC susceptibility of the R6 wt strain, R6 Δ lytA Δ lytC and R6 Δ spxB Δ lctO. This mechanism, however, appears to be exquisitely specific for Spn strains since challenging other streptococci with the pneumococcus DoC MIC₉₀ the majority of those strains were not susceptible. Studies are under way in our laboratories to identify such an enzyme and/or an additional mechanism(s).

In summary, we demonstrated *in vitro* antimicrobial activity of DoC against several pneumococcal strains, including multidrug-resistant strains, *ex vivo* antimicrobial activity to reduce colonization of human nasopharyngeal cells and *in vivo* activity that inhibited colonization in a

mouse model of pneumococcal nasopharyngeal colonization. Because Spn strains colonize billions of individuals, killing at least one million every year worldwide, data within this study bears potential for future development of prophylactic interventions aimed to reduce pneumococcal colonization.

Materials and Methods

Bacterial strains, culture media and reagents. *Streptococcus* species are listed in Table 1 and Spn reference strains and isogenic mutant derivatives are listed in Table 2. All other Spn are listed in supplemental Table 1. Strains were cultured on blood agar plates containing 5% of sheep red blood cells (BAP) from frozen stocks made in medium containing skim milk, tryptone, glucose, and glycerin (STGG) (64). Animal experiments were cultured on BAP with gentamicin (25 µg/ml). Strains were inoculated in Todd Hewitt broth containing 0.5% (w/v) yeast extract (THY) or in cation-adjusted Mueller-Hinton broth (CAMHB) with 3% of lysed horse blood [(LHB), Remel]. Paraformaldehyde (PFA), gentamicin, tetracycline, trimethoprim, and sodium deoxycholate were sourced from Sigma.

Preparation of inoculum for experiments. Inoculum was prepared essentially as previously described (65, 66). Briefly, an overnight BAP culture of the strain was used to prepare a bacterial suspension in sterile phosphate buffered saline [(PBS), pH=7.4] and the fresh bacterial suspension was inoculated to a final OD₆₀₀ of ~0.1. This suspension contained ~5.15x10⁸ cfu/ml. Aliquots of these suspensions were routinely diluted and plated to confirm bacterial counts (cfu/ml). To inoculate mice, Spn strain EF3030 was inoculated in THY broth and grown until it reached an OD₆₀₀ of ~0.2 (i.e., early log phase), then sterile glycerol was added to a final concentration of 10% and aliquots were frozen at ~-80°C. An aliquot was removed from each batch to determine the density of the preparations.

Quantitative studies of the antimicrobial activity of DoC. Studies of antimicrobial activity were performed using THY or CAMHB containing 3% of LHB. Experiments using THY were performed as follows: a bacterial suspension was inoculated in polystyrene 24-well plates (Corning) at a final density of $\sim 5.15 \times 10^8$ cfu/ml and left untreated (control) or treated with DoC at varying dosages and incubated for 2 h at 37°C in a 5% CO₂ atmosphere. To remove bacteria that could have potentially attached to the substratum, the microplate was sonicated for 15 s in a Bransonic ultrasonic water bath (Branson, Dunbury CT) and then cultures were serially diluted and plated onto BAP.

To obtain the MIC as recommended by the CLSI we utilized the broth microdilution method (34). DoC was serially diluted in CAMHB containing 3% of LHB in 96-well microtiter plates and pneumococci, that had been adjusted to a turbidity corresponding to the 0.5 McFarland standard ($\sim 1 \times 10^8$ cfu/ml), was inoculated and incubated for 20 h at 37°C. Untreated cultures and non-inoculated medium were included as a control. Besides reading the microplates as recommended by the CLSI, the untreated growth control, and wells with the obtained MIC were serially diluted and plated as before. As a control of the microdilution procedure, the MIC for tetracycline was assessed in parallel using reference strain Spn ATCC49619, and GA16833, which were sensitive (< 1 µg/ml) and resistant (8 µg/ml), respectively.

Ex-vivo model of pneumococcal colonization on human pharyngeal cells. This *ex-vivo* adhesion model on immobilized pharyngeal cells was developed by Marks et al. (2012) (67) and thereafter utilized in pathogenesis and biofilm research by different laboratories (67-69). Human pharyngeal Detroit 562 cells (ATCC CCL-198) were cultured in DMEM (Gibco) supplemented with 10% nonheat-inactivated fetal bovine serum (FBS) (Atlanta biologicals), 1% non-essential amino acids (Sigma), 1% glutamine (Sigma), penicillin (100 U/ml), streptomycin (100 µg/ml) and the pH was buffered with HEPES [(10 mM) Gibco]. Cells were incubated at 37°C in a 5% CO₂ humidified atmosphere until

confluence ~7-10 days on an 8-well glass slide (Lab-Tek), or on CellBIND® surface polystyrene 24-well plates (Corning) and then immobilized by fixation with 2% PFA for 15 min at room temperature. After extensive washes with sterile PBS, immobilized human pharyngeal cells were supplemented with cell culture medium without antibiotics and infected with an inoculum of the tested strain prepared as mentioned earlier. Infected human pharyngeal cells were incubated for 4 h at 37°C and with 5 % CO₂.

At the end of incubation, planktonic pneumococci were removed, attached bacteria were gently washed two times with sterile PBS and fresh cell culture medium with no antibiotics was added. Pneumococci attached to pharyngeal cells were challenged with DoC at different dosages at incubated for 2 h or treated with 0.5 mg/ml DoC and incubated for the indicated time at 37°C in a 5 % CO₂ atmosphere. To obtain the density of pneumococci in the 24-well plate model, pneumococci and cells were washed twice with PBS and then sonicated for 15 s in a Bransonic ultrasonic water bath (Branson, Dunburry CT) followed by extensive pipetting to remove attached bacteria. The preparations were diluted and plated onto blood agar plates to obtain bacterial counts (cfu/ml).

To stain pneumococci adhered to cells on the 8-well glass slide, bacteria were fixed with 2% PFA as before and after three washes with PBS the preparations were blocked with 2% bovine serum albumin (BSA) for 1 h at room temperature. These preparations were then incubated for 1 h with serotype-specific polyclonal antibodies (Statens Serum Institute, Denmark) (~40 µg/ml) that had been previously labeled with Alexa-488 (anti-serotype 4-Alexa-488, to stain TIGR4) or Alexa-555 (anti-serogroup 19-Alexa-555, to stain GA47281) (Molecular Probes). Stained preparations were finally washed two times with PBS. TIGR4 experiments were additionally stained with wheat germ agglutinin conjugated to Alexa-555 [(WGA), 5 µg/ml] and then mounted with ProLong Diamond Antifade mounting medium containing DAPI (Molecular Probes) whereas GA47281 preparations

were stained with TO-PRO-3 (1 μ M), a carbocyanine monomer nucleic acid stain (Molecular Probes), for 15 min. Confocal images were obtained using a Nikon AX R confocal microscope and analyzed with ImageJ version 1.49k (National Institutes of Health, USA).

Investigating the spontaneous mutation frequency. To determine the frequency of spontaneous mutation, BAP with 5% sheep red blood cells were prepared to contain either trimethoprim (1 μ g/ml) or DoC (0.5 mg/ml). Fresh suspensions of Spn strain EF3030, or TIGR4, made in PBS were prepared at a final density of $\sim 10^8$, $\sim 10^9$, $\sim 10^{10}$, $\sim 10^{11}$, and $\sim 10^{12}$ cfu/ml and inoculated on plain BAP or BAP containing trimethoprim or DoC. Bacterial suspensions were diluted and plated onto plain BAP to confirm the density of pneumococci. Inoculated plates were incubated at 37°C under a 5 % CO₂ atmosphere for ~ 20 h. The spontaneous mutation frequency was then calculated by dividing the spontaneous resistant pneumococci, i.e., grown on BAP with trimethoprim or DoC, by the bacterial population.

Mouse model of pneumococcal nasopharyngeal carriage. Three groups (N=8 each) of inbred 6-7week old C57BL/6 mice (Charles River Laboratories) were utilized to assess *in vivo* antimicrobial activity of DoC. Two groups of mice drank regular water throughout. The drinking water of the third group of mice was supplemented with DoC to a final concentration of 0.2 μ g/ml (i.e., 0.02%) starting at day 0 of the experiment, and DoC-containing water was provided *ad libitum* for remainder of the experiment (10 days). Six days after DoC was added to the drinking water of mice in group three, mice in all three groups were anesthetized with 2.5% isoflurane (vol/vol) over oxygen (2 liter/min) administered in a RC2 calibrated vaporizer (VetEquip Incorporated) and then infected with $\sim 1 \times 10^5$ cfu of Spn EF3030. Twenty-four hours post-nasal-inoculation of EF3030, mice in groups 1 and 2 were treated by nasal instillation with PBS or DoC (10 μ g each nostril), respectively, two times a day for four days. Mice were then sacrificed, and the nasopharynx, trachea, lungs and blood were

405 aseptically collected. Tissue homogenates were diluted in PBS and plated onto BAP with gentamicin.

406 Aliquots of these homogenates were supplemented to a final concentration of 10% glycerol and

407 kept at -80°C. The Institutional Animal Care and Use Committee (IACUC) at the University of

408 Mississippi Medical Center approved the protocol used in this study (1584); they oversees the

409 welfare, well-being, and proper care of all mice utilized in this study. All mouse experiments

410 followed the guidelines summarized by the National Science Foundation Animal Welfare Act (AWA).

411 **DNA extraction from nasopharyngeal homogenates and quantitative (q)PCR reactions.** DNA was

412 extracted from mouse nasopharyngeal homogenates using the Qiagen QIAmp Mini Kit. Briefly, an

413 aliquot (50 µl) of nasopharyngeal specimen was added to 100 µL of TE buffer containing 0.04 g/mL

414 lysozyme and 75 U/mL of mutanolysin. Samples were then incubated for 1 h in a 37°C water bath.

415 Following incubation, DNA was extracted from the samples following the recommended protocol

416 from the manufacturer, eluted in 100 µL of buffer AE and kept at -80°C until used. Following

417 extraction, *lytA*-based qPCR reactions were performed with primers and probe sequences published

418 by the CDC (70), the real-time PCR reagent QuantaBio PerfeCTa FastMix®, and 2.5 µL of DNA

419 template. Reactions were run in duplicate using a CFX96 Real-Time PCR Detection System (Bio-Rad)

420 at the following conditions: 1 cycle at 50°C for 2 min, 1 cycle at 95°C for 2 min and 40 cycles of 95°C

421 for 15 s, and 60°C for 1 min. Standard curves were generated under the same conditions as detailed

422 in our previous studies (71, 72). Considering the genome size of reference strain TIGR4, 2.16 Mb

423 (73), the approximate genome equivalent for each DNA standard was: 4.29×10^5 , 4.29×10^4 , 4.29×10^3 ,

424 4.29×10^2 , 4.29×10^1 , 2.14×10^1 , and 2.14 genome equivalents. Reaction efficiency of standards was

425 within the acceptable range of 90-110%.

426 **Quantification of extracellular (e)DNA.** Spn strains were inoculated into 24-well plates as detailed

427 earlier and incubated for 4 h. The culture supernatants were then harvested by centrifugation for 15

min at 14,000 x *g* in a refrigerated centrifuge (Eppendorf, Hauppauge, NY), and filter sterilized using a syringe-filter (0.4 µm). DNA was purified from 200 µl aliquots of supernatant, as mentioned above, and used as template in *lytA*-based qPCR reactions. For eDNA quantification purposes, standards containing 1x10³, 1x10², 1x10¹, 1x10⁰, 1x10⁻¹, 5x10⁻², 1x10⁻³ pg of chromosomal DNA purified from strain TIGR4 were run in parallel to generate a standard curve. The standard curve, and regression equation obtained, was then used to calculate final pg/ml using the CFX software (Bio-Rad, Hercules, CA).

Statistical analysis. Statistical analysis was performed by the non-parametric two-tailed Student *t* test, or the Mann-Whitney *U* test (comparing two groups) using the software GraphPad Prism version 9.0.0 (121).

Figure legends.

Figure 1. Deoxycholic acid kills *S. pneumoniae* strains within two hours of incubation. *S. pneumoniae* strain (A) GA47281, (B) GA44288, (C) GA17227, (D) TIGR4, or (E) D39 was inoculated at a density of ~5.15x10⁸ cfu/ml in THY broth and left untreated (control) or treated with 0.5 mg/ml or 0.25 mg/ml of deoxycholic acid (DoC). Bacteria were incubated for 2 h at 37°C in a 5% CO₂ atmosphere after which the cultures were serially diluted and plated onto blood agar plates to obtain the density (cfu/ml). Error bars represent the standard errors of the means calculated using data from at least three independent experiments. The limit of detection (LOD) was <10 cfu/ml.

Figure 2. Eradication of pneumococcal colonization with DoC using an *ex vivo* model of human pharyngeal colonization. Polarized human pharyngeal Detroit 562 cells were immobilized with 2% paraformaldehyde and then infected with *S. pneumoniae* strain GA47281 (~5.15x10⁸ cfu/ml). Infected cells were incubated for four hours and planktonic cells were removed. These *S.*

451 *pneumoniae*-colonized human pharyngeal cells were left untreated (control) or (A) treated with
 452 different dosages of deoxycholic acid (DoC) and incubated for an additional 2 h period, or (B) treated
 453 with DoC (0.5 mg/ml) and incubated for the indicated time. At the end of the incubation the cultures
 454 were serially diluted and plated onto blood agar plates to obtain the density (cfu/ml). In (A and B)
 455 error bars represent the standard errors of the means calculated using data from at least three
 456 independent experiments. * $p < 0.05$ compared to the untreated control. LOD=limit of detection. (C
 457 and D) *S. pneumoniae*-colonized human pharyngeal cells (infected as above) were left untreated or
 458 treated with DoC (0.5 mg/ml) and incubated for 2 h. Preparations were fixed and Spn was stained
 459 with (C) an anti-S19-Alexa-555 labeled antibody (red) and the DNA was stained with TOPRO3 (green)
 460 or with (D) an anti-S4-Alexa-488 labeled antibody (green), cell membranes were labeled with WGA
 461 (Red) and DNA with DAPI (blue). Preparations were analyzed by a confocal microscope. Panels show
 462 z-projections of z-stacks obtained from xy optical sections. Lower panels in (C) show a 3-D digital
 463 reconstruction. The merge of the channels is shown in each panel. Arrows point out extracellular *S.*
 464 *pneumoniae* bacteria.

465 **Figure 3. Spontaneous resistance mutation frequency of *S. pneumoniae* for trimethoprim and**
 466 **deoxycholic acid.** Bacterial suspensions prepared with fresh cultures of *S. pneumoniae* strain
 467 EF3030, or TIGR4, were adjusted to a density of $\sim 10^8$, $\sim 10^9$, $\sim 10^{10}$, $\sim 10^{11}$, and $\sim 10^{12}$ cfu/ml and
 468 inoculated onto blood agar plates (BAP) containing trimethoprim (Tmp, 1 μ g/ml) or deoxycholic acid
 469 (DoC, 0.5 mg/ml). Each inoculum was further diluted and plated onto plain BAP. All cultures were
 470 incubated for 20 h after which bacteria were counted. The spontaneous mutation frequency (smF)
 471 was calculated by dividing the number of spontaneous resistant pneumococci, i.e., grown on BAP
 472 with trimethoprim or DoC, by the bacterial population. Error bars represent the standard errors of

the means calculated using data from at least three independent experiments. The median smF is shown on each bar.

Figure 4. Deoxycholic acid kills pneumococci with a deficient autolytic mechanism. (A) *S. pneumoniae* strain R6 wt, or isogenic double mutants $\Delta lytA\Delta lytC$ or $\Delta spxB\Delta lctO$ were inoculated in six-well plates containing THY and bacteria were incubated for 4 h. The supernatants were obtained, filter sterilized and eDNA was purified. This eDNA was used as a template in species-specific quantitative (q)PCR reactions along with DNA standards for quantification purposes. *statistical significance, $p < 0.037$, compared to R6 wt. (B) R6 wt or its isogenic $\Delta lytA\Delta lytC$ mutant was inoculated at a density of $\sim 5.15 \times 10^8$ cfu/ml in THY broth and left untreated (control) or treated with 0.5 mg/ml of DoC. Bacteria were incubated for 2 h at 37°C in a 5% CO₂ atmosphere after which the cultures were serially diluted and plated onto blood agar plates to obtain the density (cfu/ml). # $p = 0.33$ compared to R6 wt strain treated with DoC. In panels A and B error bars represent the standard errors of the means calculated using data from at least three independent experiments.

Figure 5. Deoxycholic acid (0.5 mg/ml) does not affect the viability of other streptococcal species. (A) *S. pneumoniae* strain EF3030, (B) *S. oralis*, (C) *S. mutans*, (D) *S. gordonii*, or (E) *S. anginosus* was inoculated at a density of $\sim 5.15 \times 10^8$ cfu/ml in THY broth and left untreated (control) or treated with 0.5 mg/ml deoxycholic acid (DoC). Bacteria were incubated for 2 h at 37°C in a 5% CO₂ atmosphere after which the cultures were serially diluted and plated onto blood agar plates to obtain the density (cfu/ml). Error bars represent the standard errors of the means calculated using data from at least three independent experiments. *statistical significance, $p < 0.04$, compared to the untreated EF3030 control.

Figure 6. Revisiting the mouse model of pneumococcal nasopharyngeal carriage. C57BL/6 mice (N=5) were intranasally inoculated with *S. pneumoniae* EF3030 ($\sim 1 \times 10^5$ cfu). After 48 h mice were

euthanized and the nasal bone was removed to expose the (A) nasopharynx, arrow. The nasopharynx, trachea and lungs were removed. (B) The nasopharynges were sectioned (~5 µm) and stained with hematoxylin and eosin. Arrowhead=microvilli, dotted line=connective tissue. Nasopharyngeal (NP) tissue, trachea, and lungs were homogenized and (C) NP homogenate was stained with DAPI and with an anti-S19-Alexa-555 antibody, or (D) homogenates were diluted and plated onto BAP with gentamicin (25 µg/ml) to obtain the bacterial density (cfu/ml). (E) NP tissue stained with TOTO-1 and with an anti-S19-Alexa-555 antibody; arrows=pneumococci (red). The micrographs in C and D are z-projections of z-stacks obtained from xy optical sections collected with a confocal microscope.

Figure 7. Prophylactic treatment with deoxycholic acid inhibits pneumococcal colonization in a mouse model of colonization. (A) Experimental design. Three groups of mice (N=8) were utilized; groups 1 and 2 drank regular water throughout whereas group 3 was prophylactically (pro) treated by adding DoC (0.2 µg/ml) to their drinking water at day 0. At day 6, all three groups were infected with *S. pneumoniae* EF3030. Twenty-four hours post inoculation, mice in groups 1 and 2 were treated via intranasal (nasal) inoculation with PBS (Ctrl) or DoC (10 µg each nostril) two times a day for four days. All mice were sacrificed at day 10 and the nasopharynx, trachea, lungs and blood were collected. (B) Mice in all three groups were weighed at days 0 and 10. (C) Nasopharyngeal specimens were homogenized, diluted, and plated onto BAP with gentamicin (25 µg/ml) to obtain bacterial density (cfu/ml). (D) DNA was extracted from nasopharyngeal homogenates and used in species-specific *lytA*-based qPCR reactions. In panels B and C =**p*>0.249 (NS), or ***p*<0.003, compared with control mice.

Supplemental figure 1. Deoxycholic acid kill *S. pneumoniae* strain TIGR4 inoculated into CAMHB with 3% lysed horse blood. *S. pneumoniae* strain TIGR4 was inoculated at a density of ~5.15x10⁸

cfu/ml into CAMHB-LHB and left untreated (control) or treated with 0.5, 1, or 2 mg/ml of deoxycholic acid (DoC). Bacteria were incubated ~20 h at 37°C in a 5% CO₂ atmosphere after which the cultures were serially diluted and plated onto blood agar plates to obtain the density (cfu/ml). Error bars represent the standard errors of the means calculated using data from at least three independent experiments. The median density is shown inside the control bar or above DoC (0.5). Limit of detection (LOD) was <10 cfu/ml.

Acknowledgements

This study was in part supported by grants from the National Institutes of Health (NIH; 1R21AI144571-01, and 1R21AI151571-01A1 to JEV). BA was supported by a Fulbright scholarship awarded by the US Department of State. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH or the US Department of State. We thank Dr. Yih-Ling Tzeng and Dr. David Stephens from Emory University School of Medicine and Dr. Lesley McGee from the Centers for Disease Control and Prevention (CDC) for providing *S. pneumoniae* strains. We also thanks Dr. Miriam Moscoso from “Centro de Investigaciones Biologicas” in Madrid, Spain for providing the autolysin knockout mutant. Special thanks to Dr. Gene L. Bidwell (Cell and Molecular Biology) and Joshua R. Jefferson (Pathology) at UMMC for providing assistance with confocal microscopy and histology studies, respectively. Landon Murin from the Murrah-UMMC base pair program for his assistance in some laboratory procedures.

539 References

- 540 1. Shak JR, Vidal JE, Klugman KP. 2013. Influence of bacterial interactions on pneumococcal
541 colonization of the nasopharynx. *Trends Microbiol* 21:129-35.
- 542 2. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, Pneumococcal Carriage G.
543 2012. The fundamental link between pneumococcal carriage and disease. *Expert Rev*
544 *Vaccines* 11:841-55.
- 545 3. Arguedas A, Trzcinski K, O'Brien KL, Ferreira DM, Wyllie AL, Weinberger D, Danon L, Pelton SI,
546 Azzari C, Hammitt LL, Sa-Leao R, Brandileone MC, Saha S, Suaya J, Isturiz R, Jodar L, Gessner
547 BD. 2020. Upper respiratory tract colonization with *Streptococcus pneumoniae* in adults.
548 *Expert Rev Vaccines* 19:353-366.
- 549 4. Dunne EM, Smith-Vaughan HC, Robins-Browne RM, Mulholland EK, Satzke C. 2013.
550 Nasopharyngeal microbial interactions in the era of pneumococcal conjugate vaccination.
551 *Vaccine* 31:2333-42.
- 552 5. Krone CL, Wyllie AL, van Beek J, Rots NY, Oja AE, Chu ML, Bruin JP, Bogaert D, Sanders EA,
553 Trzcinski K. 2015. Carriage of *Streptococcus pneumoniae* in aged adults with influenza-like-
554 illness. *PLoS One* 10:e0119875.
- 555 6. Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M. 2011. Early acquisition and
556 high nasopharyngeal co-colonisation by *Streptococcus pneumoniae* and three respiratory
557 pathogens amongst Gambian new-borns and infants. *BMC Infect Dis* 11:175.
- 558 7. Nelson KN, Grijalva CG, Chochua S, Hawkins PA, Gil AI, Lanata CF, Griffin MR, Edwards KM,
559 Klugman KP, Vidal JE. 2018. Dynamics of Colonization of *Streptococcus pneumoniae* Strains
560 in Healthy Peruvian Children. *Open Forum Infect Dis* 5:ofy039.
- 561 8. Sutcliffe CG, Grant LR, Cloessner E, Klugman KP, Vidal JE, Reid R, Colelay J, Weatherholtz RC,
562 Chochua S, Jacobs MR, Santosham M, O'Brien KL, Hammitt LL. 2019. Association of
563 Laboratory Methods, Colonization Density, and Age With Detection of *Streptococcus*
564 *pneumoniae* in the Nasopharynx. *Am J Epidemiol* 188:2110-2119.
- 565 9. Wyllie AL, Rumke LW, Arp K, Bosch A, Bruin JP, Rots NY, Wijmenga-Monsuur AJ, Sanders
566 EAM, Trzcinski K. 2016. Molecular surveillance on *Streptococcus pneumoniae* carriage in
567 non-elderly adults; little evidence for pneumococcal circulation independent from the
568 reservoir in children. *Sci Rep* 6:34888.
- 569 10. van Deursen AM, van den Bergh MR, Sanders EA, Carriage Pilot Study G. 2016. Carriage of
570 *Streptococcus pneumoniae* in asymptomatic, community-dwelling elderly in the
571 Netherlands. *Vaccine* 34:4-6.
- 572 11. Lai CC, Wang CY, Hsueh PR. 2020. Co-infections among patients with COVID-19: The need for
573 combination therapy with non-anti-SARS-CoV-2 agents? *J Microbiol Immunol Infect*
574 doi:10.1016/j.jmii.2020.05.013.
- 575 12. Dananche C, Paranhos-Baccala G, Messaoudi M, Sylla M, Awasthi S, Bavdekar A, Sanghavi S,
576 Diallo S, Pape JW, Rouzier V, Chou M, Eap T, Rakoto-Andrianarivelo M, Maeder M, Wang J,
577 Ren L, Dash-Yandag B, Nymadawa P, Guillen R, Russomando G, Endtz H, Komurian-Pradel F,
578 Vanhems P, Sanchez Picot V. 2020. Serotypes of *Streptococcus pneumoniae* in Children Aged
579 <5 Years Hospitalized With or Without Pneumonia in Developing and Emerging Countries: A
580 Descriptive, Multicenter Study. *Clin Infect Dis* 70:875-883.
- 581 13. Weiser JN, Ferreira DM, Paton JC. 2018. *Streptococcus pneumoniae*: transmission,
582 colonization and invasion. *Nat Rev Microbiol* 16:355-367.

- 583 14. Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. 2013. Impact of pneumococcal conjugate
584 vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people:
585 review of evidence on indirect effects. *Vaccine* 32:133-45.
- 586 15. Klugman KP. 2001. Efficacy of pneumococcal conjugate vaccines and their effect on carriage
587 and antimicrobial resistance. *Lancet Infect Dis* 1:85-91.
- 588 16. O'Brien KL, Dagan R. 2003. The potential indirect effect of conjugate pneumococcal vaccines.
589 *Vaccine* 21:1815-25.
- 590 17. Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. 2014. Effect of 13-
591 valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its
592 introduction in the USA: a time series analysis. *Lancet Respir Med* 2:387-94.
- 593 18. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhon MA, Cherian T, Levine OS, Whitney CG,
594 O'Brien KL, Moore MR. 2013. Serotype-specific changes in invasive pneumococcal disease
595 after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple
596 surveillance sites. *PLoS Med* 10:e1001517.
- 597 19. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K,
598 Parkinson A. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among
599 alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.
600 *Jama* 297:1784-92.
- 601 20. Weinberger DM, Malley R, Lipsitch M. 2011. Serotype replacement in disease after
602 pneumococcal vaccination. *Lancet* 378:1962-73.
- 603 21. Winkler ES, Shrihari S, Hykes BL, Jr., Handley SA, Andhey PS, Huang YS, Swain A, Droit L,
604 Chebrolu KK, Mack M, Vanlandingham DL, Thackray LB, Cella M, Colonna M, Artyomov MN,
605 Stappenbeck TS, Diamond MS. 2020. The Intestinal Microbiome Restricts Alphavirus
606 Infection and Dissemination through a Bile Acid-Type I IFN Signaling Axis. *Cell* 182:901-918
607 e18.
- 608 22. Sun X, Winglee K, Gharaibeh RZ, Gauthier J, He Z, Tripathi P, Avram D, Bruner S, Fodor A,
609 Jobin C. 2018. Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice.
610 *Gastroenterology* 154:1751-1763 e2.
- 611 23. Wang H, Latorre JD, Bansal M, Abraha M, Al-Rubaye B, Tellez-Isaias G, Hargis B, Sun X. 2019.
612 Microbial metabolite deoxycholic acid controls *Clostridium perfringens*-induced chicken
613 necrotic enteritis through attenuating inflammatory cyclooxygenase signaling. *Sci Rep*
614 9:14541.
- 615 24. Boyer JL. 2013. Bile formation and secretion. *Compr Physiol* 3:1035-78.
- 616 25. Wahlstrom A, Sayin SI, Marschall HU, Backhed F. 2016. Intestinal Crosstalk between Bile
617 Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metab* 24:41-50.
- 618 26. Foley MH, O'Flaherty S, Barrangou R, Theriot CM. 2019. Bile salt hydrolases: Gatekeepers of
619 bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract. *PLoS*
620 *Pathog* 15:e1007581.
- 621 27. Woollett LA, Buckley DD, Yao L, Jones PJ, Granholm NA, Tolley EA, Tso P, Heubi JE. 2004.
622 Cholic acid supplementation enhances cholesterol absorption in humans. *Gastroenterology*
623 126:724-31.
- 624 28. Kamalpour S, Leblanc K, Jr. 2016. Injection Adipolysis: Mechanisms, Agents, and Future
625 Directions. *J Clin Aesthet Dermatol* 9:44-50.
- 626 29. Amore R, Amuso D, Leonardi V, Leva F, Sibaud AC, Guida A, Costa E, Terranova F, Amodeo V,
627 Gkritzalas K. 2018. Evaluation of Safe and Effectiveness of an Injectable Solution Acid

Deoxycholic Based for Reduction of Localized Adiposities. *Plast Reconstr Surg Glob Open* 6:e1794.

30. Winston JA, Rivera AJ, Cai J, Thanissery R, Montgomery SA, Patterson AD, Theriot CM. 2020. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during *Clostridioides difficile* Infection by Altering Gut Bile Acids. *Infect Immun* 88.
31. McDonald JAK, Mullish BH, Pechlivanis A, Liu Z, Brignardello J, Kao D, Holmes E, Li JV, Clarke TB, Thursz MR, Marchesi JR. 2018. Inhibiting Growth of *Clostridioides difficile* by Restoring Valerate, Produced by the Intestinal Microbiota. *Gastroenterology* 155:1495-1507 e15.
32. Olivera C, Le VVH, Davenport C, Rakonjac J. 2021. In vitro synergy of 5-nitrofurans, vancomycin and sodium deoxycholate against Gram-negative pathogens. *J Med Microbiol* 70.
33. Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee IK, Yun BS, Matsuzaki K, Furukawa M, Min HK, Bajaj JS, Zhou H, Hylemon PB. 2019. Bile Acid 7 α -Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit *Clostridium difficile*: Role of Secondary Bile Acids. *Cell Chem Biol* 26:27-34 e4.
34. Institute. CaLS. 2020. Performance Standards for Antimicrobial Susceptibility Testing. Thirtieth Informational Supplement. M100-S30. Wayne, PA.
35. Henderson-Begg SK, Livermore DM, Hall LM. 2006. Effect of subinhibitory concentrations of antibiotics on mutation frequency in *Streptococcus pneumoniae*. *J Antimicrob Chemother* 57:849-54.
36. Eldholm V, Johnsborg O, Haugen K, Ohnstad HS, Havarstein LS. 2009. Fratricide in *Streptococcus pneumoniae*: contributions and role of the cell wall hydrolases CbpD, LytA and LytC. *Microbiology* 155:2223-2234.
37. Havarstein LS, Martin B, Johnsborg O, Granadel C, Claverys JP. 2006. New insights into the pneumococcal fratricide: relationship to clumping and identification of a novel immunity factor. *Mol Microbiol* 59:1297-307.
38. Wu X, Gordon O, Jiang W, Antezana BS, Angulo-Zamudio UA, Del Rio C, Moller A, Brissac T, Tierney ARP, Warncke K, Orihuela CJ, Read TD, Vidal JE. 2019. Interaction between *Streptococcus pneumoniae* and *Staphylococcus aureus* Generates (.)OH Radicals That Rapidly Kill *Staphylococcus aureus* Strains. *J Bacteriol* 201.
39. Bryant JC, Dabbs RC, Oswalt KL, Brown LR, Rosch JW, Seo KS, Donaldson JR, McDaniel LS, Thornton JA. 2016. Pyruvate oxidase of *Streptococcus pneumoniae* contributes to pneumolysin release. *BMC Microbiol* 16:271.
40. Echlin H, Frank M, Rock C, Rosch JW. 2020. Role of the pyruvate metabolic network on carbohydrate metabolism and virulence in *Streptococcus pneumoniae*. *Mol Microbiol* doi:10.1111/mmi.14557.
41. Junges R, Maienschein-Cline M, Morrison DA, Petersen FC. 2019. Complete Genome Sequence of *Streptococcus pneumoniae* Serotype 19F Strain EF3030. *Microbiol Resour Announc* 8.
42. Scott EJ, 2nd, Luke-Marshall NR, Campagnari AA, Dyer DW. 2019. Draft Genome Sequence of Pediatric Otitis Media Isolate *Streptococcus pneumoniae* Strain EF3030, Which Forms In Vitro Biofilms That Closely Mimic In Vivo Biofilms. *Microbiol Resour Announc* 8.
43. Puchta A, Verschoor CP, Thurn T, Bowdish DM. 2014. Characterization of inflammatory responses during intranasal colonization with *Streptococcus pneumoniae*. *J Vis Exp* doi:10.3791/50490:e50490.

- 673 44. Keller LE, Luo X, Thornton JA, Seo KS, Moon BY, Robinson DA, McDaniel LS. 2015.
674 Immunization with Pneumococcal Surface Protein K of Nonencapsulated *Streptococcus*
675 *pneumoniae* Provides Protection in a Mouse Model of Colonization. *Clin Vaccine Immunol*
676 22:1146-53.
- 677 45. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine
678 MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. 2019.
679 Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical
680 Practice Guideline of the American Thoracic Society and Infectious Diseases Society of
681 America. *Am J Respir Crit Care Med* 200:e45-e67.
- 682 46. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC,
683 Roberts HJ, Levy ML, Wani M, Woodhead MA, Pneumonia Guidelines Committee of the
684 BTSSoCC. 2009. BTS guidelines for the management of community acquired pneumonia in
685 adults: update 2009. *Thorax* 64 Suppl 3:iii1-55.
- 686 47. Northfield TC, McColl I. 1973. Postprandial concentrations of free and conjugated bile acids
687 down the length of the normal human small intestine. *Gut* 14:513-8.
- 688 48. Vertzoni M, Archontaki H, Reppas C. 2008. Determination of intraluminal individual bile
689 acids by HPLC with charged aerosol detection. *J Lipid Res* 49:2690-5.
- 690 49. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P,
691 Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic
692 treatment of *clostridium difficile* carrier mice triggers a supershedder state, spore-mediated
693 transmission, and severe disease in immunocompromised hosts. *Infect Immun* 77:3661-9.
- 694 50. Sipka S, Bruckner G. 2014. The immunomodulatory role of bile acids. *Int Arch Allergy*
695 *Immunol* 165:1-8.
- 696 51. Keating N, Keely SJ. 2009. Bile acids in regulation of intestinal physiology. *Curr Gastroenterol*
697 *Rep* 11:375-82.
- 698 52. Lajczak NK, Saint-Criq V, O'Dwyer AM, Perino A, Adorini L, Schoonjans K, Keely SJ. 2017. Bile
699 acids deoxycholic acid and ursodeoxycholic acid differentially regulate human beta-defensin-
700 1 and -2 secretion by colonic epithelial cells. *FASEB J* 31:3848-3857.
- 701 53. Choucair I, Nemet I, Li L, Cole MA, Skye SM, Kirsop JD, Fischbach MA, Gogonea V, Brown JM,
702 Tang WHW, Hazen SL. 2020. Quantification of bile acids: a mass spectrometry platform for
703 studying gut microbe connection to metabolic diseases. *J Lipid Res* 61:159-177.
- 704 54. Danese E, Negrini D, Pucci M, De Nitto S, Ambrogi D, Donzelli S, Lievens PM, Salvagno GL,
705 Lippi G. 2020. Bile Acids Quantification by Liquid Chromatography-Tandem Mass
706 Spectrometry: Method Validation, Reference Range, and Interference Study. *Diagnostics*
707 (Basel) 10.
- 708 55. Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ. 2018. The bile acids, deoxycholic acid and
709 ursodeoxycholic acid, regulate colonic epithelial wound healing. *Am J Physiol Gastrointest*
710 *Liver Physiol* 314:G378-G387.
- 711 56. Wadsworth A. 1903. The Agglutination of the *Pneumococcus* with certain Normal and
712 Immune Sera. *J Med Res* 10:228-42.
- 713 57. Sadowy E, Hryniewicz W. 2020. Identification of *Streptococcus pneumoniae* and other *Mitis*
714 *streptococci*: importance of molecular methods. *Eur J Clin Microbiol Infect Dis* 39:2247-2256.
- 715 58. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo
716 AM, Leach AJ, Klugman KP, Porter BD, Sa-Leao R, Scott JA, Nohynek H, O'Brien KL, Group
717 WHOPCW. 2013. Standard method for detecting upper respiratory carriage of *Streptococcus*

pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine* 32:165-79.

59. Slotved HC, Facklam RR, Fuursted K. 2017. Assessment of a novel bile solubility test and MALDI-TOF for the differentiation of *Streptococcus pneumoniae* from other mitis group streptococci. *Sci Rep* 7:7167.

60. Mundy LS, Janoff EN, Schwebke KE, Shanholtzer CJ, Willard KE. 1998. Ambiguity in the identification of *Streptococcus pneumoniae*. Optochin, bile solubility, quellung, and the AccuProbe DNA probe tests. *Am J Clin Pathol* 109:55-61.

61. Cortes PR, Orio AG, Regueira M, Pinas GE, Echenique J. 2008. Characterization of in vitro-generated and clinical optochin-resistant strains of *Streptococcus pneumoniae* isolated from Argentina. *J Clin Microbiol* 46:1930-4.

62. Weight CM, Venturini C, Pojar S, Jochems SP, Reine J, Nikolaou E, Solorzano C, Noursadeghi M, Brown JS, Ferreira DM, Heyderman RS. 2019. Microinvasion by *Streptococcus pneumoniae* induces epithelial innate immunity during colonisation at the human mucosal surface. *Nat Commun* 10:3060.

63. Mosser JL, Tomasz A. 1970. Choline-containing teichoic acid as a structural component of pneumococcal cell wall and its role in sensitivity to lysis by an autolytic enzyme. *J Biol Chem* 245:287-98.

64. O'Brien KL, Bronsdon MA, Dagan R, Yagupsky P, Janco J, Elliott J, Whitney CG, Yang YH, Robinson LG, Schwartz B, Carlone GM. 2001. Evaluation of a medium (STGG) for transport and optimal recovery of *Streptococcus pneumoniae* from nasopharyngeal secretions collected during field studies. *J Clin Microbiol* 39:1021-4.

65. Vidal JE, Ludewick HP, Kunkel RM, Zahner D, Klugman KP. 2011. The LuxS-dependent quorum-sensing system regulates early biofilm formation by *Streptococcus pneumoniae* strain D39. *Infect Immun* 79:4050-60.

66. Wu X, Jacobs NT, Bozio C, Palm P, Lattar SM, Hanke CR, Watson DM, Sakai F, Levin BR, Klugman KP, Vidal JE. 2017. Competitive Dominance within Biofilm Consortia Regulates the Relative Distribution of Pneumococcal Nasopharyngeal Density. *Appl Environ Microbiol* 83.

67. Marks LR, Parameswaran GI, Hakansson AP. 2012. Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo. *Infect Immun* 80:2744-60.

68. Vidal JE, Howery KE, Ludewick HP, Nava P, Klugman KP. 2013. Quorum-sensing systems LuxS/autoinducer 2 and Com regulate *Streptococcus pneumoniae* biofilms in a bioreactor with living cultures of human respiratory cells. *Infect Immun* 81:1341-53.

69. Wholey WY, Kochan TJ, Storck DN, Dawid S. 2016. Coordinated Bacteriocin Expression and Competence in *Streptococcus pneumoniae* Contributes to Genetic Adaptation through Neighbor Predation. *PLoS Pathog* 12:e1005413.

70. Carvalho Mda G, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, Steigerwalt A, Whaley M, Facklam RR, Fields B, Carlone G, Ades EW, Dagan R, Sampson JS. 2007. Evaluation and improvement of real-time PCR assays targeting *lytA*, *ply*, and *psaA* genes for detection of pneumococcal DNA. *J Clin Microbiol* 45:2460-6.

71. Sakai F, Sonaty G, Watson D, Klugman KP, Vidal JE. 2017. Development and characterization of a synthetic DNA, NUversa, to be used as a standard in quantitative polymerase chain reactions for molecular pneumococcal serotyping. *FEMS Microbiol Lett* 364.

- 762 72. Sakai F, Chochua S, Satzke C, Dunne EM, Mulholland K, Klugman KP, Vidal JE. 2015. Single-
763 plex quantitative assays for the detection and quantification of most pneumococcal
764 serotypes. PLoS One 10:e0121064.
- 765 73. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft
766 DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White
767 O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen
768 CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F,
769 Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM. 2001.
770 Complete genome sequence of a virulent isolate of *Streptococcus pneumoniae*. Science
771 293:498-506.
- 772 74. Lanie JA, Ng WL, Kazmierczak KM, Andrzejewski TM, Davidsen TM, Wayne KJ, Tettelin H,
773 Glass JI, Winkler ME. 2007. Genome sequence of Avery's virulent serotype 2 strain D39 of
774 *Streptococcus pneumoniae* and comparison with that of unencapsulated laboratory strain
775 R6. J Bacteriol 189:38-51.
- 776 75. McDevitt E, Khan F, Scasny A, Thompson CD, Eichenbaum Z, McDaniel LS, Vidal JE. 2020.
777 Hydrogen Peroxide Production by *Streptococcus pneumoniae* Results in Alpha-hemolysis by
778 Oxidation of Oxy-hemoglobin to Met-hemoglobin. mSphere 5.
- 779 76. Moscoso M, Garcia E, Lopez R. 2006. Biofilm formation by *Streptococcus pneumoniae*: role
780 of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J Bacteriol
781 188:7785-95.
- 782 77. Andersson B, Dahmen J, Frejd T, Leffler H, Magnusson G, Noori G, Eden CS. 1983.
783 Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci
784 attaching to human pharyngeal epithelial cells. J Exp Med 158:559-70.
- 785 78. Schroeder MR, Lohsen S, Chancey ST, Stephens DS. 2019. High-Level Macrolide Resistance
786 Due to the Mega Element [mef(E)/mel] in *Streptococcus pneumoniae*. Front Microbiol
787 10:868.

788

789

790 **Table 1. Antimicrobial activity of DoC against streptococcal species.**

Strain	MIC ₉₀ (mg/ml)*,#	791
<i>S. pneumoniae</i> ATCC BAA-255	0.25	792
<i>S. australis</i> ATCC 700641	>1	793
<i>S. cristatus</i>	>0.5	794
<i>S. infantis</i> ATCC 700779	>0.5	795
<i>S. intermedius</i> ATCC 27335	>0.5	796
<i>S. intestinalis</i> ATCC 43492	>1	797
<i>S. oligofermentus</i> CDC SS-1725	>1	798
<i>S. parasanguinis</i> ATCC 15912	>0.5	799
<i>S. peroris</i> ATCC 700780	>0.5	800
<i>S. pseudopneumoniae</i> ATCC BAA-960	0.5	801
<i>S. salivarius</i> ATCC 7073	0.5	802
<i>S. sanguinis</i> ATCC 10556	>1	
<i>S. sinensis</i> CDC SS-1726	>0.5	
<i>D. pilgrum</i>	>0.5	
<i>S. sobrinus</i> ATCC 33478	>2	

803 *Strains were challenged with the MIC₉₀ for *S. pneumoniae* strains (0.5 mg/ml). #The limit of
804 detection of this assay was 50 cfu/ml.

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

Strain	Description**	Reference or source
TIGR4	Invasive clinical isolate, capsular serotype 4, sensitive to antibiotics	(73)
D39	Avery strain, clinical isolate, capsular serotype 2; sensitive to antibiotics	(74)
R6	D39-derivative unencapsulated laboratory strain, sensitive to antibiotics	(74)
R6Δ <i>spxB</i> Δ <i>lctO</i>	R6-derivative, hydrogen peroxide and autolysis deficient strain.	(75)
R6Δ <i>lytA</i> Δ <i>lytC</i>	R6-derivative, autolysis deficient strain.	(76)
EF3030	Clinical isolate, capsular serotype 19F, sensitive to antibiotics	(41, 77)
<i>S. pneumoniae</i> ATCC49619	Invasive reference strain, recommended by the CLSI* for antimicrobial sensitive test serotype 19F	American Type Culture Collection, (34)
GA44288	Clinical isolate, capsular serotype 19A; ERY, TET, AMX, CXM, CLI, SXT, MEM, PEN, CRO, CTX	(78)
GA47281	Clinical isolate, capsular serotype 19F; ERY, TET, AMX, CXM, CLI, SXT, MEM, PEN, CRO, CTX	(78)
GA16833	Clinical isolate, capsular serotype 19F; ERY,	(78)

	TET, CXM,	834	*CL
GA17227	Clinical isolate, capsular serotype 23F; ERY,	(78)	SI,
	TET,	836	clini
		837	cal
		838	and

laboratory standards institute. **Resistance to: amoxicillin (AMX), cefuroxime (CXM), ceftriaxone (CRO), cefotaxime (CTX), clindamycin (CLI), erythromycin (ERY), meropenem (MEM), penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole (SXT)

Figure 1, Vidal et al

Figure 2, Vidal et al

Figure 3, Vidal et al

Figure 4, Vidal et al

Figure 5, Vidal et al

Figure 6, Vidal et al

Figure 7, Vidal et al